Name | Number of supported studies | Average coverage | |
---|---|---|---|
brain | 18 studies | 41% ± 21% | |
lung | 10 studies | 28% ± 8% | |
liver | 5 studies | 31% ± 19% | |
peripheral blood | 4 studies | 25% ± 2% | |
heart | 4 studies | 29% ± 4% | |
eye | 4 studies | 38% ± 18% | |
adipose | 4 studies | 31% ± 11% | |
intestine | 3 studies | 19% ± 1% | |
kidney | 3 studies | 24% ± 7% |
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 100% | 9751.15 | 1445 / 1445 | 100% | 58.45 | 183 / 183 |
lung | 100% | 10525.52 | 578 / 578 | 100% | 48.13 | 1155 / 1155 |
breast | 100% | 10224.96 | 459 / 459 | 100% | 64.29 | 1117 / 1118 |
prostate | 100% | 9389.31 | 245 / 245 | 100% | 50.51 | 501 / 502 |
thymus | 100% | 9430.20 | 653 / 653 | 100% | 48.13 | 602 / 605 |
intestine | 100% | 9875.62 | 966 / 966 | 99% | 39.75 | 524 / 527 |
brain | 99% | 5870.74 | 2623 / 2642 | 100% | 42.53 | 705 / 705 |
bladder | 100% | 9813.76 | 21 / 21 | 99% | 36.71 | 499 / 504 |
stomach | 100% | 7511.95 | 359 / 359 | 99% | 42.09 | 283 / 286 |
uterus | 100% | 9314.55 | 170 / 170 | 99% | 37.85 | 454 / 459 |
ovary | 100% | 8637.71 | 180 / 180 | 99% | 28.64 | 425 / 430 |
kidney | 100% | 7076.74 | 89 / 89 | 98% | 42.24 | 884 / 901 |
skin | 100% | 12224.40 | 1809 / 1809 | 98% | 54.69 | 462 / 472 |
pancreas | 97% | 4206.11 | 318 / 328 | 99% | 43.83 | 177 / 178 |
liver | 100% | 4241.27 | 225 / 226 | 96% | 22.79 | 391 / 406 |
adrenal gland | 100% | 9755.71 | 258 / 258 | 95% | 31.12 | 219 / 230 |
adipose | 100% | 10992.26 | 1204 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 10584.72 | 1335 / 1335 | 0% | 0 | 0 / 0 |
lymph node | 0% | 0 | 0 / 0 | 100% | 52.29 | 29 / 29 |
muscle | 100% | 12768.96 | 803 / 803 | 0% | 0 | 0 / 0 |
spleen | 100% | 10664.08 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 45.43 | 45 / 45 |
ureter | 0% | 0 | 0 / 0 | 100% | 13.25 | 1 / 1 |
peripheral blood | 99% | 9683.13 | 921 / 929 | 0% | 0 | 0 / 0 |
heart | 96% | 6640.80 | 829 / 861 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 95% | 28.87 | 76 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
GO_0006974 | Biological process | DNA damage response |
GO_0006511 | Biological process | ubiquitin-dependent protein catabolic process |
GO_0006281 | Biological process | DNA repair |
GO_0045995 | Biological process | regulation of embryonic development |
GO_0000209 | Biological process | protein polyubiquitination |
GO_0043161 | Biological process | proteasome-mediated ubiquitin-dependent protein catabolic process |
GO_0140861 | Biological process | DNA repair-dependent chromatin remodeling |
GO_0033696 | Biological process | heterochromatin boundary formation |
GO_0016607 | Cellular component | nuclear speck |
GO_0005654 | Cellular component | nucleoplasm |
GO_0005829 | Cellular component | cytosol |
GO_0005634 | Cellular component | nucleus |
GO_0046966 | Molecular function | nuclear thyroid hormone receptor binding |
GO_0061630 | Molecular function | ubiquitin protein ligase activity |
GO_0005515 | Molecular function | protein binding |
Gene name | TRIP12 |
Protein name | E3 ubiquitin-protein ligase TRIP12 (EC 2.3.2.26) (E3 ubiquitin-protein ligase for Arf) (ULF) (HECT-type E3 ubiquitin transferase TRIP12) (Thyroid receptor-interacting protein 12) (TR-interacting protein 12) (TRIP-12) Thyroid hormone receptor interactor 12 E3 ubiquitin-protein ligase (EC 2.3.2.26) Alternative protein TRIP12 |
Synonyms | hCG_1811426 ULF KIAA0045 |
Description | FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair . Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins . Acts as a key regulator of DNA damage response by acting as a suppressor of RNF168, an E3 ubiquitin-protein ligase that promotes accumulation of 'Lys-63'-linked histone H2A and H2AX at DNA damage sites, thereby acting as a guard against excessive spreading of ubiquitinated chromatin at damaged chromosomes . In normal cells, mediates ubiquitination and degradation of isoform p19ARF/ARF of CDKN2A, a lysine-less tumor suppressor required for p53/TP53 activation under oncogenic stress . In cancer cells, however, isoform p19ARF/ARF and TRIP12 are located in different cell compartments, preventing isoform p19ARF/ARF ubiquitination and degradation . Does not mediate ubiquitination of isoform p16-INK4a of CDKN2A . Also catalyzes ubiquitination of NAE1 and SMARCE1, leading to their degradation . Ubiquitination and degradation of target proteins is regulated by interaction with proteins such as MYC, TRADD or SMARCC1, which disrupt the interaction between TRIP12 and target proteins . Mediates ubiquitination of ASXL1: following binding to N(6)-methyladenosine methylated DNA, ASXL1 is ubiquitinated by TRIP12, leading to its degradation and subsequent inactivation of the PR-DUB complex . . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase involved in ubiquitin fusion degradation (UFD) pathway and regulation of DNA repair. Part of the ubiquitin fusion degradation (UFD) pathway, a process that mediates ubiquitination of protein at their N-terminus, regardless of the presence of lysine residues in target proteins. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. . FUNCTION: E3 ubiquitin-protein ligase which accepts ubiquitin from an E2 ubiquitin-conjugating enzyme in the form of a thioester and then directly transfers the ubiquitin to targeted substrates. . |
Accessions | ENST00000453485.2 A0A6Q8PGG9 A0A994J752 A0A994J4J6 C9JLJ5 ENST00000704583.1 ENST00000389044.8 [Q14669-3] G5E9G6 ENST00000675903.1 ENST00000430954.6 A0A994J569 A0A994J7J0 Q14669 ENST00000704580.1 [Q14669-2] A0A6Q8PHK0 Q57Z94 ENST00000283943.9 [Q14669-1] ENST00000428959.5 ENST00000704577.1 ENST00000704585.1 C9JSX9 ENST00000675453.1 A0A994J4S0 ENST00000704582.1 ENST00000704581.1 ENST00000704579.1 ENST00000389045.7 [Q14669-4] F8W9P3 ENST00000409677.5 L0R5E3 ENST00000675423.1 A0A994J4J0 A0A994J755 C9JLD7 H7C2Y1 ENST00000435716.5 ENST00000343290.5 H7C1L9 ENST00000418123.1 ENST00000704584.1 ENST00000704578.1 |